LAUSR

Bioresorbable scaffolds (BRS) were conceived and created to overcome the structural limitations of metallic drug‐eluting stents. Complete scaffold reabsorption represents the ideal process to guarantee the restoring of endothelial function and vasomotion, avoiding neoatherosclerosis and the subsequent risk of adverse coronary events. Unfortunately, the early excitement about this innovative product faced the harsh reality deriving from randomized clinical trials (RCT): 3‐year rate of target lesion failure (TLF) was significantly higher in patients treated with the Absorb Bioresorbable Vascular Scaffolds (BVS) compared to those treated with cobalt‐chromium everolimus‐eluting stents (EES). The unexpected negative results led to Absorb withdrawal from the market. Several potential causes, such as structural properties of the device, wrong patient/lesion selection, and suboptimal scaffold deployment have been proposed to explain the negative outcomes.